RCT | Empagliflozin (SGLT2i) is more effective for reducing HbA1c than linagliptin (DPP-4i) in young people with Type 2 DM

Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial – The Lancet Diabetes & Endocrinology (link to abstract – $ for full-text)

Commentaries:

DINAMO: Empagliflozin shows promise for young people with type 2 diabetes – medwire News

Phase 3 trial finds oral empagliflozin provides safe glycemic control in children with type 2 diabetes – Joslin Diabetes Center